Medivation Rejects Sanofi Takeover Bid

Source: Bloomberg

Apr 29, 2016

San Francisco-based Medivation Inc. has rejected Sanofi's $9.3 billion takeover offer, claiming that the French drugmaker’s bid undervalues the cancer-treatment company.

Sanofi said it will go directly the Medivation shareholders with its offer of $52.50 per Medivation share.

Medivation offers prostate cancer drug, Xtandi, and is developing other oncology treatments for breast cancer.

Read the Bloomberg coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments